Evidence map›Paper›PMID 29042620›Full record

ArticleScientific reports2017

An Integrin-Targeted, Highly Diffusive Construct for Photodynamic Therapy.

Oliver J Klein, Hushan Yuan, Nicholas H Nowell, Charalambos Kaittanis, Lee Josephson, Conor L Evans

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Rapid, user-friendly, and inexpensive detection of azidothymidine.Analytical and bioanalytical chemistry · 2021
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oliver J KleinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 13th St, CNY149, Charlestown, MA, 02129, USA.
Hushan YuanDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, 13th St, CNY149, Charlestown, MA, 02129, USA.
Nicholas H NowellWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 13th St, CNY149, Charlestown, MA, 02129, USA.
Charalambos KaittanisDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, 13th St, CNY149, Charlestown, MA, 02129, USA.
Lee JosephsonDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, 13th St, CNY149, Charlestown, MA, 02129, USA.
Conor L EvansWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 13th St, CNY149, Charlestown, MA, 02129, USA. evans.conor@mgh.harvard.edu.

Funding

Imaging and Overcoming Hypoxia-Induced Resistance in Metastatic Ovarian CancerDP2OD007096 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI EVANS, CONOR LEE · 2010 to 2010
$2.7M
PEG-like Multimodal Nanoprobes for Imaging Enhanced Permeability RetentionR01EB017699 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI NORMANDIN, MARC DAVID · 2014 to 2017
$1.6M
NIBIB NIH HHS R01 EB017699NIH HHS DP2 OD007096
6 · The paper itself

Abstract

Targeted antineoplastic agents show great promise in the treatment of cancer, having the ability to impart cytotoxicity only to specific tumor types. However, these therapies do not experience uniform uptake throughout tumors, leading to sub-lethal cell killing that can impart treatment resistance, and cause problematic off-target effects. Here we demonstrate a photodynamic therapy construct that integrates both a cyclic RGD moiety for integrin-targeting, as well as a 5 kDa PEG chain that passivates the construct and enables its rapid diffusion throughout tumors. PEGylation of the photosensitizer construct was found to prevent photosensitizer aggregation, boost the generation of cytotoxic reactive radical species, and enable the rapid uptake of the construct into cells throughout large (>500 µm diameter) 3D tumor spheroids. Replacing the cyclic RGD with the generic RAD peptide led to the loss of cellular uptake in 3D culture, demonstrating the specificity of the construct. Photodynamic therapy with the construct was successful in inducing cytotoxicity, which could be competitively blocked by a tenfold concentration of free cyclic RGD. This construct is a first-of-its kind theranostic that may serve as a new approach in our growing therapeutic toolbox.

Indexed as

LightPhotochemotherapyAntineoplastic AgentsBiological TransportCell Line, TumorCell SurvivalHumansIntegrinsIntracellular SpaceMolecular StructurePhotosensitizing AgentsPolyethylene GlycolsProtein BindingReactive Oxygen SpeciesThiazines5-ethylamino-9-diethylaminobenzo(a)phenothiaziniumAntineoplastic AgentsIntegrinsPhotosensitizing AgentsPolyethylene GlycolsReactive Oxygen SpeciesThiazines

Identifiers

PMID29042620
PMCPMC5645319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.